-
Mashup Score: 36Outcomes in studies regarding older patients with prostate cancer: A systematic review - 13 day(s) ago
Older patients are often deemed ineligible for clinical research, and many frequently-used endpoints and outcome measures are not as relevant for older patients for younger ones. This systematic review aimed to present an overview of outcomes used in clinical research regarding patients over the age of 65ย years with prostate cancer.
Source: www.geriatriconcology.netCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Both randomized controlled trials (RCTs) and retrospective studies have shown that a comprehensive geriatric assessment (CGA) prior to a patient commencing systemic anti-cancer therapy (SACT) results in improved quality of life outcomes and is associated with a decreased risk of grade 3โ5 toxicity; however, data are lacking in relation to adverse drug events (ADE) associated with supportive care medications. Supportive care medications are prescribed as prophylactic agents in a SACT regimen, for management of treatment related toxicity and for symptoms caused by the disease itself.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review - 1 month(s) ago
Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor- (CAR-) T cell therapies are essential treatment modalities for many hematological malignancies. Although their use in older adults has substantially increased within the past decades, cellular therapies represent intensive treatment approaches that exclude a large percentage of older adults due to comorbidities and frailty. Under- and overtreatment in older adults with hematologic malignancy is a challenge and many treatment decisions are influenced by chronologic age.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper - 2 month(s) ago
Immune checkpoint inhibitors (ICIs) became a treatment option in most tumor types and improved survival in patients with cancer in the last decade. Older patients with cancer are underrepresented in the pivotal clinical trials with ICIs. Older patients with cancer often have significant comorbidities and geriatric syndromes like frailty, which can complicate cancer care and treatment decisions. Frailty is among the most prevalent geriatric syndromes in patients with cancer and could lead to inferior survival and a higher risk of complications in patients treated with chemotherapy.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper - 2 month(s) ago
Immune checkpoint inhibitors (ICIs) became a treatment option in most tumor types and improved survival in patients with cancer in the last decade. Older patients with cancer are underrepresented in the pivotal clinical trials with ICIs. Older patients with cancer often have significant comorbidities and geriatric syndromes like frailty, which can complicate cancer care and treatment decisions. Frailty is among the most prevalent geriatric syndromes in patients with cancer and could lead to inferior survival and a higher risk of complications in patients treated with chemotherapy.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18
Older patients are often excluded from clinical trials with the majority of patients being between the ages of 18 and 64 [1]. This may be due to increased incidence of medical comorbidities in the older adults as well as poorer performance status, but often this is a result of clinical selection bias for suitability for clinical trials [1,2]. Early phase clinical trials (EPCTs) aim to assess the tolerability and toxicity profile of novel anti-cancer therapeutics. The primary goal is to determine dose limiting toxicity (DLT) in order to move forward within the drug development timeline.
Source: www.geriatriconcology.netCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 30Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper - 2 month(s) ago
Immune checkpoint inhibitors (ICIs) became a treatment option in most tumor types and improved survival in patients with cancer in the last decade. Older patients with cancer are underrepresented in the pivotal clinical trials with ICIs. Older patients with cancer often have significant comorbidities and geriatric syndromes like frailty, which can complicate cancer care and treatment decisions. Frailty is among the most prevalent geriatric syndromes in patients with cancer and could lead to inferior survival and a higher risk of complications in patients treated with chemotherapy.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Immunotherapy use in older adults with cancer with frailty: A young SIOG review paper - 2 month(s) ago
Immune checkpoint inhibitors (ICIs) became a treatment option in most tumor types and improved survival in patients with cancer in the last decade. Older patients with cancer are underrepresented in the pivotal clinical trials with ICIs. Older patients with cancer often have significant comorbidities and geriatric syndromes like frailty, which can complicate cancer care and treatment decisions. Frailty is among the most prevalent geriatric syndromes in patients with cancer and could lead to inferior survival and a higher risk of complications in patients treated with chemotherapy.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9
Patient falls in the hospital lead to adverse outcomes and impaired quality of life. Older adults with cancer who are frail may be at heightened risk of falls in the postoperative period. We sought to evaluate the association between degree of preoperative frailty and risk of inpatient postoperative falls and other outcomes among older adults with cancer.
Source: www.geriatriconcology.netCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Trends in wearable device use among cancer survivors in the United States from 2019 to 2022 - 2 month(s) ago
The increasing digitization of healthcare has driven the rise in wearable devices, notably during the COVID-19 pandemic. Wearable devices continuously track patients’ physiological measurements, such as heart rate, activity, sleep, etc. For patients with cancer, these digital biomarkers may reflect meaningful variation in physical function, symptom burden, quality of life, and risk of adverse events, [1] and have the potential to improve physical activity and quality of life. [2] Despite the growing popularity and recognized benefits of wearable devices, research suggests a low uptake and digital divide in both healthy adults [3] and those with chronic diseases (e.g., cardiovascular disease) [4].
Source: www.geriatriconcology.netCategories: General Medicine News, Onc News and JournalsTweet
Outcomes in studies regarding older patients with prostate cancer: A systematic review https://t.co/3x6ETNdbSn @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #ProstateCancer #OlderPatients #StudyOutcomes https://t.co/IkbBtnWFNo